Moderna
Develops mRNA-based medicines for health
Manufacturing Associate 2 - Process Development
+ Annual discretionary bonus + Other incentive compensation + Equity award
Site-based role requiring full-time on-site work; remote work is not available.
About the job
- Hands-on experience in a biotechnology manufacturing, development, quality, or laboratory environment.
- Ability to execute procedures independently with attention to detail and strong documentation discipline.
- Ability to practice Good Laboratory Practices, Good Documentation Practices, and accurate material tracking.
- Ability to identify and communicate process, equipment, material, documentation, or safety issues with clear context.
- Ability to support troubleshooting through accurate observations, execution details, and process understanding.
- Bachelor of Science or Bachelor of Arts degree in Chemistry, Systems, Biomedical Engineering, Chemical Engineering, or a closely related field.
- Zero to two years of related experience.
- Demonstrated success in bioprocess development, technical problem solving, and technology transfer.
- Ability to multitask.
- Strong written and oral communication.
- Ability to work full-time on site; the position is not eligible for remote work.
- Execute established Lipid Nanoparticle and/or Drug Product unit operations according to approved procedures and laboratory expectations.
- Lead established manufacturing processes once trained and qualified.
- Prepare materials, buffers, equipment, and work areas for manufacturing execution.
- Operate, clean, and maintain laboratory and pilot-scale equipment.
- Maintain work areas according to safety and 5S expectations.
- Identify and communicate process, equipment, material, documentation, and safety issues.
- Support troubleshooting by providing accurate observations, execution details, and process understanding.
- Support onboarding, peer training, continuous improvement, and operational excellence activities.
- Hands-on experience with tangential flow filtration.
About the company
Moderna develops medicines built on messenger RNA (mRNA). Its products use mRNA delivered into cells to instruct them to produce specific proteins that can prevent or treat disease, with vaccines being a primary example. In practice, a dose delivers engineered mRNA into the body, cells translate it into a target protein, and the immune system responds or the protein modulates biology to combat disease. Moderna differentiates itself through its focus on building a whole mRNA medicines platform and in-house capabilities for designing, manufacturing, and scaling mRNA therapies, including rapid development and large-scale production. Its goal is to create a new category of medicines based on mRNA that can improve how diseases are discovered, developed, and treated, ultimately improving patient outcomes.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2010
Get referred to Moderna
See people who can refer or advise you
Simplify's Take
What believers are saying
- FDA approved updated 2026-2027 Spikevax and mNEXSPIKE on August 27, 2026.
- Moderna raised $2.6 billion in convertible notes on August 28, 2026, extending runway.
- ESMO Presidential Symposium on October 24, 2026 spotlights intismeran and attracts oncology investors.
What critics are saying
- Sanofi's September 2026 New Jersey suit threatens costly IP fights over COVID vaccine patents.
- EPO revoked Moderna's key mRNA patent on September 18, 2026, weakening leverage.
- COVID demand still funds operations; oncology failure after October 24 ESMO would expose existential dependence.
What makes Moderna unique
- Moderna and Merck's intismeran hit Phase 3 melanoma success on August 19, 2026.
- Its mRNA platform spans vaccines, oncology, and rare-disease programs across nine cancer trials.
- Moderna controls proprietary mRNA manufacturing and lipid nanoparticle know-how built since 2010.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Sick Leave
Paid Holidays
Sabbatical Leave
Hybrid Work Options
401(k) Company Match
Parental Leave
Family Planning Benefits
Fertility Treatment Support
Adoption Assistance
Wellness Program
Mental Health Support
Phone/Internet Stipend
Home Office Stipend
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -1%2 year growth
↑ 0%Bob Langer, co-founder of Moderna, has joined the scientific advisory board of Cellular Intelligence, a biotech company focused on AI-driven drug development. The appointment follows Cellular Intelligence's recent acquisition of a Parkinson's cell therapy programme. Langer's role connects Moderna's mRNA expertise with AI medicine collaborations. The move aligns with efforts to use AI and advanced analytics to improve R&D productivity and drug discovery. Moderna, a US-based biotechnology company with a market value of about $69 billion, develops messenger RNA medicines across multiple regions. The company's links to AI-driven discovery and new cell therapies may influence how its research pipeline evolves over time.
Moderna is repositioning itself as an oncology mRNA platform company after its personalised cancer vaccine, intismeran autogene, met its primary endpoint in a Phase 3 melanoma trial. The vaccine, co-developed with Merck, targets neoantigens and is being tested across nine trials in multiple tumour types. The company announced a $2.6 billion convertible note raise to fund its pipeline. Executives acknowledged that the main challenge is hospital implementation of the required biopsy, tumour sequencing and bespoke mRNA manufacturing workflow. Moderna and Merck are building site-by-site teams to address these operational hurdles. Full trial data will be presented at ESMO in late October. The programme includes three Phase 3 lung studies, with kidney and bladder trial readouts expected within approximately one year.
Moderna Stock Jumped 12% yesterday. An ESMO Presidential slot explains Why. Last updated Sep 22, 2026 jittawit21 from jittawit21 and TEK IMAGE/SCIENCE PHOTO LIBRARY from sciencephoto Key Takeaways. * Presidential Symposium Slot: Moderna stock jumped 12% to $173 on September 21 after Phase 3 melanoma data for its cancer vaccine, intismeran autogene, earned a spot in ESMO's Presidential Symposium on October 24. * Vaccine Clearance: The FDA cleared updated Spikevax and mNEXSPIKE shots targeting the JN.1-lineage XFG variant the same day, reinforcing Moderna's respiratory revenue base heading into flu season. * Street Lag: Analysts have penciled in a $120 mean target against the $173 close, with 4 buys, 1 outperform, 16 holds, 1 underperform and 1 sell among the 23 covering the stock, a gap of 31% below where shares now sit. * Coverage Thinning: Price-target coverage fell from 22 analysts a year ago to 18. Moderna stock (MRNA) trades 31% above the mean target that 23 analysts have penciled in. See how the Street prices oncology upside on TIKR for free Why Moderna Stock Jumped 12% on ESMO's Presidential Symposium News. Moderna (MRNA) stock jumped 12% to $173 on Monday, September 21, after the company said Phase 3 melanoma data for its personalized cancer vaccine will headline a Presidential Symposium slot at the European Society for Medical Oncology Congress on October 24. Three abstracts on the therapy, intismeran autogene, were accepted for the Madrid conference. Only one made the Presidential Symposium, the slot ESMO reserves for data organizers see as capable of changing how oncologists treat patients. The trial behind it, INTerpath-001, pairs intismeran autogene with Merck's Keytruda against Keytruda alone in resected melanoma. It is a personalized therapy, built from a patient's own tumor mutations rather than off a shelf. Moderna President Stephen Hoge previewed the stakes a week earlier at Morgan Stanley 24th Annual Global Healthcare Conference, saying the drug delivered "the first time we've ever - anybody has ever achieved that kind of benefit over Keytruda in the adjuvant setting in melanoma." That framing matters. Keytruda already works well in this setting, so beating it changes the ceiling for what a T-cell priming vaccine can do across other tumors Moderna is testing it in, including lung, bladder and renal cell cancer. Monday's jump did not happen in isolation. Moderna stock had already climbed roughly 30% since late August as investors positioned ahead of the ESMO readout, and Monday's confirmation pushed shares within reach of their 52-week high near $177. Options activity and momentum buying likely amplified the single-day pop on top of the fundamental news. The move reprices Moderna as an oncology story first and a vaccine maker second, and that shift is what the rest of this article measures against the Street. Moderna Stock Also Got a Lift From FDA Vaccine Clearances. The same day, the FDA cleared Moderna's updated 2026-2027 Spikevax and mNEXSPIKE shots targeting the JN.1-lineage XFG variant, the strain regulators picked for this year's COVID season. That clearance was not the headline, but it removed a piece of uncertainty around Moderna's base respiratory business right as flu season approaches. mNEXSPIKE already captured roughly a quarter of the U.S. retail COVID vaccine market in its first season, and the XFG update keeps that franchise current. Layered onto the melanoma news, it gave investors two separate reasons to buy Moderna stock in the same session instead of one. Moderna Stock's Mean Target Trails the Rally by 31%. Moderna stock closed at $173 on September 21. The 23 analysts covering the name put a mean target of $120 on it, split between 4 buys, 1 outperform, 16 holds, 1 underperform and 1 sell. That mean sits 31% below where shares now trade, so the median investor recommendation is still hold even after Monday's pop. The gap didn't open overnight. Moderna's stock price climbed from $28 in June 2025 to $173 by September 21, 2026, roughly six-fold. The mean target rose too, from $48 to $120, but much slower. The Target/Close ratio fell from above 170% in mid-2025 to 69% by September. Targets kept rising. The stock kept outrunning them. Coverage thinned too, from 22 analysts to 18, even as underperforms dropped from 3 to 1. That's a Street playing catch-up, not calling the top. October 24 decides whether $120 moves toward $173, or the stock cools first. Should You Invest in Moderna, Inc.? The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question. Pull up Moderna, Inc. stock and you'll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down. Looking for New Opportunities? * See what stocks billionaire investors are buying so you can follow the smart money. * Analyze stocks in as little as 5 minutes with TIKR's all-in-one, easy-to-use platform. * The more rocks you overturn... the more opportunities you'll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR. Disclaimer: Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or its content team, nor are they recommendations to buy or sell any stocks. TIKR create its content based on TIKR Terminal's investment data and analysts' estimates. Its analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing! Table of Contents * Key Takeaways * Why Moderna Stock Jumped 12% on ESMO's Presidential Symposium News * Moderna Stock Also Got a Lift From FDA Vaccine Clearances * Moderna Stock's Mean Target Trails the Rally by 31% * Should You Invest in Moderna, Inc.? * Looking for New Opportunities? * Disclaimer: Stock Reviews
Moderna announces late-breaking data to be presented at ESMO Congress 2026. Phase 3 data for intismeran autogene in the adjuvant treatment of patients with resected stage IIB-IV melanoma selected for presentation at a Presidential Symposium Moderna to host an investor event via webcast on Saturday, October 24, at 7:00 PM CEST / 1:00 PM EDT CAMBRIDGE, Mass., September 21, 2026 (Newswire.com) - Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on intismeran autogene, an investigational mRNA-based individualized neoantigen therapy, have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, which will be held October 23-27 in Madrid, Spain. The presentation details are as follows: Presidential Symposium: * LBA1- INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL) Session Type/Title: Presidential Symposium Date & Time: Saturday, October 24, 4:30 PM CEST / 10:30 AM EDT Presenter: Georgina V. Long (Sydney, Australia, NSW) Poster Presentations: * Abstract 3151P: Adjuvant intismeran autogene plus FOLFIRINOX in resectable pancreatic ductal adenocarcinoma: results from a phase I study Session Type/Title: Poster - Pancreatic cancer Date & Time: Sunday, October 25, 12:00-12:45 PM CET Presenter: David J. Pinato (London, United Kingdom) * Abstract 2550TiP: INTerpath-014: A Phase 3 Study of Adjuvant Intismeran Autogene (Intismeran) Plus Subcutaneous Pembrolizumab (Pembro SC) or Intismeran Monotherapy vs Placebo in Completely Resected High-Risk Stage I NSCLC Session Type/Title: Poster - NSCLC, early stage Date & Time: Monday, October 26, 12:00-12:45 PM CET Presenter: Charu Aggarwal (Philadelphia, United States of America) Intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada. Moderna Investor Event Moderna will host a live webcast on Saturday, October 24, at 7:00 PM CEST / 1:00 PM EDT. The webcast will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation. About Moderna Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more. With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn. Moderna Contacts Chris Ridley Vice President, Global Head of Communications +1 617-800-3651 [email protected] Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 [email protected]
Moderna announces late-breaking data to be presented at ESMO Congress 2026. Moderna (MRNA) will present late-breaking and additional clinical data on intismeran autogene, its investigational mRNA-based individualized neoantigen therapy, at the ESMO Congress 2026 in Madrid from October 23-27. (Moderate) (Very Positive) Rhea-AI summary. Moderna (MRNA) will present late-breaking and additional clinical data on intismeran autogene, its investigational mRNA-based individualized neoantigen therapy, at the ESMO Congress 2026 in Madrid from October 23-27. The company's Phase 3 melanoma study INTerpath-001 (intismeran plus pembrolizumab vs pembrolizumab alone) is scheduled in the Presidential Symposium on Saturday, October 24, at 4:30 PM CEST / 10:30 AM EDT. Two poster sessions will cover a Phase I study in resectable pancreatic ductal adenocarcinoma (Sunday, October 25, 12:00-12:45 PM CET) and the Phase 3 INTerpath-014 trial in high-risk stage I NSCLC (Monday, October 26, 12:00-12:45 PM CET). Intismeran autogene is jointly developed by Moderna and Merck (MSD outside the US and Canada). Moderna will also host a live investor webcast on Saturday, October 24, at 7:00 PM CEST / 1:00 PM EDT, with a replay available for at least 30 days. Argus 15 min delay +12.96% vs previous close $174.01 last price 1.4x rel. volume Open Argus * Accepted abstracts - 3 abstracts - ESMO Congress 2026 * Presidential Symposium presentation - October 24, 2026 - INTerpath-001 Phase 3 study * Pancreatic cancer poster - October 25, 2026 - Phase I study * NSCLC poster - October 26, 2026 - INTerpath-014 Phase 3 study AI-generated analysis. How Rhea-AI works. Not financial advice. See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google 09/21/2026 - 07:12 AM CAMBRIDGE, MA / ACCESS Newswire / September 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on intismeran autogene, an investigational mRNA-based individualized neoantigen therapy, have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, which will be held October 23-27 in Madrid, Spain. The presentation details are as follows: Presidential Symposium: * LBA1- INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL) Session Type/Title: Presidential Symposium Date & Time: Saturday, October 24, 4:30 PM CEST / 10:30 AM EDT Presenter: Georgina V. Long (Sydney, Australia, NSW) Poster Presentations: * Abstract 3151P: Adjuvant intismeran autogene plus FOLFIRINOX in resectable pancreatic ductal adenocarcinoma: results from a phase I study Session Type/Title: Poster - Pancreatic cancer Date & Time: Sunday, October 25, 12:00-12:45 PM CET Presenter: David J. Pinato (London, United Kingdom) * Abstract 2550TiP: INTerpath-014: A Phase 3 Study of Adjuvant Intismeran Autogene (Intismeran) Plus Subcutaneous Pembrolizumab (Pembro SC) or Intismeran Monotherapy vs Placebo in Completely Resected High-Risk Stage I NSCLC Session Type/Title: Poster - NSCLC, early stage Date & Time: Monday, October 26, 12:00-12:45 PM CET Presenter: Charu Aggarwal (Philadelphia, United States of America) Intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada. Moderna Investor Event Moderna will host a live webcast on Saturday, October 24, at 7:00 PM CEST / 1:00 PM EDT. The webcast will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation. About Moderna Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how Stock Titan treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more. With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with Stock Titan on X, Facebook, Instagram, YouTube and LinkedIn. Moderna Contacts Chris Ridley Vice President, Global Head of Communications +1 617-800-3651 [email protected] Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 [email protected] Faq. AI-generated questions and answers. How Rhea-AI works. Not financial advice. When and where will the Phase 3 INTerpath-001 melanoma data on intismeran autogene be presented? The INTerpath-001 Phase 3 melanoma study of intismeran autogene plus pembrolizumab versus pembrolizumab alone will be presented in the ESMO 2026 Presidential Symposium on Saturday, October 24, at 4:30 PM CEST / 10:30 AM EDT in Madrid, Spain. What other cancer indications for intismeran autogene will be discussed at ESMO 2026? Additional presentations cover a Phase I study of adjuvant intismeran autogene plus FOLFIRINOX in resectable pancreatic ductal adenocarcinoma (poster session on Sunday, October 25, 12:00-12:45 PM CET) and the Phase 3 INTerpath-014 adjuvant study in completely resected high-risk stage I NSCLC (poster session on Monday, October 26, 12:00-12:45 PM CET). How can investors access Moderna's event related to the ESMO 2026 presentations? Moderna will host a live webcast on Saturday, October 24, at 7:00 PM CEST / 1:00 PM EDT. It will be available under "Events and Presentations" in the Investors section of the company's website at investors.modernatx.com, with a replay archived for at least 30 days.